-
This study investigates the role of metabolic dysregulation of the insulin-glucose axis and the risk of obesity-related cancers in the Framingham Heart Study Offspring Cohort over approximately 37 years. The authors found that impaired fasting glucose exposure for a period greater than 10 years increased obesity-related cancer risk.
-
A systematic review and meta-analysis of randomized controlled trials of meditation programs demonstrated moderate strength of evidence for mindfulness meditation for improving anxiety, depression, and pain.
-
This study reviews a recent example of hepatotoxicity from a dietary supplement and discusses the issues related to retroactively monitoring nutritional supplements for adverse effects.
-
The recent publication of the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) and the continuing introduction of new psychoactive drugs create challenges for updated diagnostic and therapeutic choices for primary care patients.
-
Type 1 diabetes is associated with an increased risk of mortality, secondary to microvascular (neuropathy, nephropathy) and macrovascular (coronary artery disease, stroke, peripheral vascular disease) complications.
-
-
Bioprosthetic aorta valves are recommended for those > 70 years of age because of their reduced durability compared to mechanical valves and mechanical prostheses, which are recommended for those < 60 years because bioprosthetic valves deteriorate more rapidly in younger individuals.
-
Due to the short half-life and rapid onset of action of the new oral anticoagulants (NOACs), peri-procedural anticoagulant free time intervals should be shorter than with warfarin. Thus, there is uncertainty about the use of heparin bridging.
-
Although not a life-threatening condition, benign prostatic hypertrophy (BPH) is one of the most annoying and troublesome problems that plagues aging males.
-
Because of its strong efficacy, long-term durability, and predictability when titrated with algorithms employed in clinical trials, basal insulin remains a mainstay of treatment for type 2 diabetes patients who are not able to attain or maintain glycemic control with oral agents alone. Because diabetes is a progressive disorder, even patients who are initially well-controlled on basal insulin will likely require “fine tuning” of their diabetes regimen, usually with agents that preferentially affect postprandial glucose levels.